MRC Technology and NYU School of Medicine have signed an agreement to develop an antibody for the prevention of inflammatory osteolysis (bone breakdown).
Heptares Therapeutics (Heptares) recently announced the grant of multiple key patents in the United States relating to its GPCR-focused drug discovery platform.
MRC Technology and Shandong International Biotechnology Park (BIOasis) have signed a partnership agreement for the development of…
The Neurodegeneration Medicines Acceleration Programme (Neuro-MAP), led by medical research charity MRC Technology, will see charities and funding bodies identify promising drug projects no longer in development and help scientists to take them forward to the next stage. Drugs for brain diseases such as dementia, motor neurone disease and Parkinson’s could be revived.
The initiative will focus on identification of novel druggable targets in the field of small molecules and antibodies, and collaborating to fast track those targets through drug discovery to create potent and selective novel therapeutics. It brings together EMBLEM’s experience in supporting academics in one of the world’s leading locations for scientific research, with MRC Technology’s dedicated expertise in translating novel biology targets into lead stage therapeutic assets.
MRC Technology's Director of Drug Discovery, Justin Bryans, is quoted in a Nature Biotechnology article about the…
A collaboration between MRC Technology and Dr Andrew Blanks at the University of Warwick has been launched to develop inhibitors of inwardly rectifying potassium channel kir7.1 for the treatment of postpartum haemorrhage.